ArticleCell reports2020
A Positive Feedback Loop of TET3 and TGF-β1 Promotes Liver Fibrosis.
Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- TET3 promotes preeclampsia by regulating PDK4-mediated glucose metabolism reprogramming in trophoblasts.iScience · 2026Article
- Fibroblast-specific palladin drives kidney fibrosis via MRTF-SRF signaling.The Journal of pathology · 2026Article
- Hepatitis C virus core protein-induced myeloid-derived suppressor cells promote hepatic fibrosis by regulating hepatic stellate cell function via TGF-β.Frontiers in immunology · 2026Article
- Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer.Cell reports. Medicine · 2025Article
- TET3 is a regulator and can be targeted for the intervention of myocardial fibrosis.EMBO molecular medicine · 2025Article
- [Two-sample Mendelian randomization analysis for the causal relationship between 91 circulating inflammatory proteins and liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease.EMBO molecular medicine · 2025Article
- Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- TET3-overexpressing macrophages promote endometriosis.The Journal of clinical investigation · 2024Article
- New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?Journal of personalized medicine · 2024Review
- Skeletal muscle TET3 promotes insulin resistance through destabilisation of PGC-1α.Diabetologia · 2024Article
- Effects of metformin on parasitological, pathological changes in the brain and liver and immunological aspects during visceral toxocariasis in mice.Parasitology research · 2023Article
- Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).Science translational medicine · 2023Review
- TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.Respiratory research · 2023Article
- TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease.Scientific reports · 2023Article
- miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression.Hepatology international · 2023Article
- Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation.Biomedicines · 2023Review
- Protein Acetylation Increased Risk of Fibrosis-Related Liver Cancer.Journal of oncology · 2023Article
- TET3 epigenetically controls feeding and stress response behaviors via AGRP neurons.The Journal of clinical investigation · 2022Article
- The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Pathological activation of TGF-β signaling is universal in fibrosis. Aberrant TGF-β signaling in conjunction with transdifferentiation of hepatic stellate cells (HSCs) into fibrogenic myofibroblasts plays a central role in liver fibrosis. Here we report that the DNA demethylase TET3 is anomalously upregulated in fibrotic livers in both humans and mice. We demonstrate that in human HSCs, TET3 promotes profibrotic gene expression by upregulation of multiple key TGF-β pathway genes, including TGFB1. TET3 binds to target gene promoters, inducing demethylation, which in turn facilitates chromatin remodeling and transcription. We also reveal a positive feedback loop between TGF-β1 and TET3 in both HSCs and hepatocytes. Furthermore, TET3 knockdown ameliorates liver fibrosis in mice. Our results uncover a TET3/TGF-β1 positive feedback loop as a crucial determinant of liver fibrosis and suggest that inhibiting TET3 may represent a therapeutic strategy for liver fibrosis and perhaps other fibrotic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.